MOUNJARO prices in the UK could double as the manufacturer will next month hike the rate it charges pharmacies for the fat ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

A sweeping analysis of global studies reveals that stopping weight loss drugs, including well-known treatments like Ozempic and Wegovy, often triggers a rapid return of lost pounds.

More than one in four U.S. adults with diabetes used one of the injectable medicines that target the GLP-1 protein last year, ...

One study found a modest risk of developing non-arteritic anterior ischaemic optic neuropathy (NAOIN), a rare eye condition ...

There is zero evidence that ​​semaglutides can increase the size of your crown jewels. What may happen is that as you lose ...

Surging medical costs, pricey new drugs, and the looming end of enhanced subsidies could push ACA Marketplace premiums to ...

In this retrospective study, patients who started a GLP-1 agonist experienced significant declines in hidradenitis ...

The North Carolina Department of Health and Human Services will slash Medicaid spending by $319 million effective Oct. 1, ...

Texas has sued pharmaceutical giant Eli Lilly for allegedly bribing and illegally inducing medical providers to prescribe its ...

Last and least, I look at the drug stocks and I can’t believe how awful they really are, with now Eli Lilly last joining the ...

The Q2 pharma earnings season featured changes in the obesity race as well as insights into drugmakers’ views on tariffs and drug pricing.